Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Dare Bioscience (DARE) EBITDA Margin (2016 - 2025)

Dare Bioscience (DARE) has disclosed EBITDA Margin for 6 consecutive years, with 157201.86% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin fell 14597745.0% year-over-year to 157201.86%, compared with a TTM value of 30627.16% through Sep 2025, up 3081574.0%, and an annual FY2024 reading of 42125.02%, down 4105051.0% over the prior year.
  • EBITDA Margin was 157201.86% for Q3 2025 at Dare Bioscience, down from 18909.83% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 57604.15% in Q2 2024 and bottomed at 157201.86% in Q3 2025.
  • Average EBITDA Margin over 4 years is 17447.39%, with a median of 553.96% recorded in 2023.
  • Peak annual rise in EBITDA Margin hit 5587668bps in 2025, while the deepest fall reached -14597745bps in 2025.
  • Year by year, EBITDA Margin stood at 2.78% in 2022, then plummeted by -10042bps to 276.51% in 2023, then surged by 3266bps to 8755.45% in 2024, then crashed by -1895bps to 157201.86% in 2025.
  • Business Quant data shows EBITDA Margin for DARE at 157201.86% in Q3 2025, 18909.83% in Q2 2025, and 17167.64% in Q1 2025.